[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,585
  • Shares Outstanding, K 11,305
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,120 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.48

Options Overview Details

View History
  • Implied Volatility 321.28% (+55.77%)
  • Historical Volatility 119.13%
  • IV Percentile 52%
  • IV Rank 31.21%
  • IV High 857.88% on 02/18/26
  • IV Low 77.80% on 01/30/26
  • Expected Move (DTE 17) 0.81 (23.68%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 451
  • Open Int (30-Day) 339
  • Expected Range 2.60 to 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) +185,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +75.35%
on 05/12/26
3.74 -6.23%
on 05/28/26
+1.39 (+65.42%)
since 05/01/26
3-Month
1.11 +215.94%
on 03/27/26
3.74 -6.23%
on 05/28/26
+0.69 (+24.36%)
since 02/27/26
52-Week
1.11 +215.94%
on 03/27/26
5.74 -38.95%
on 08/06/25
+0.46 (+14.98%)
since 05/30/25

Most Recent Stories

More News
New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2026 / New to The Street announces tonight's Bloomberg Television broadcast airing at 6:30 PM ET as sponsored programming across the United States, MENA, and...

RDZN : 1.9400 (+3.19%)
HIT : 1.0850 (+9.36%)
GROY : 3.18 (-2.15%)
IGC : 0.2817 (-2.49%)
LTRN : 3.62 (+0.84%)
MDCX : 0.3450 (-8.97%)
DVLT : 0.5461 (+9.22%)
New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology

Featured companies include Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holding Limited (NASDAQ:YYGH), and FreeCast (NASDAQ:AST). The show also broadcasts as sponsored programming...

RDZN : 1.9400 (+3.19%)
AST : 0.94 (-0.53%)
IGC : 0.2817 (-2.49%)
VTIX : 3.81 (+2.97%)
AST.VN : 0.030 (+50.00%)
LTRN : 3.62 (+0.84%)
MDCX : 0.3450 (-8.97%)
YYGH : 0.1969 (+3.63%)
DVLT : 0.5461 (+9.22%)
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONICâ„¢ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

The FDA raised no objections to Lantern's key proposed protocol amendments to the HARMONICâ„¢ clinical trial. Amendments include: (1) enriching enrollment for patients with EGFR exon...

LTRN : 3.62 (+0.84%)
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing...

LTRN : 3.62 (+0.84%)
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering...

LTRN : 3.62 (+0.84%)
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering...

LTRN : 3.62 (+0.84%)
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Lantern Pharma Inc. (NASDAQ: LTRN ), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning...

LTRN : 3.62 (+0.84%)
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

Planned additions are designed to expand and enhance withZeta.ai’s capabilities, including: real-time, multi-omic computational analyses; simultaneous, highly parallel multi-agentic reasoning, and enterprise-grade...

LTRN : 3.62 (+0.84%)
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

360-Degree Small-Molecule Developability Profiling from a Single SMILES String in Seconds by characterizing and calculating 99 critical molecular features ...

LTRN : 3.62 (+0.84%)
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global

Sponsored Programming Supported by Commercials from Medicus Pharma (NASDAQ:MDCX), IGC Pharma (NYSE American:IGC), Roadzen (NASDAQ:RDZN), and Lantern Pharma (NASDAQ:LTRN)

RDZN : 1.9400 (+3.19%)
IGC : 0.2817 (-2.49%)
LTRN : 3.62 (+0.84%)
NRXP : 4.77 (+7.92%)
MDCX : 0.3450 (-8.97%)
CISO : 0.4151 (-6.80%)

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 3.95
2nd Resistance Point 3.78
1st Resistance Point 3.68
Last Price 3.62
1st Support Level 3.41
2nd Support Level 3.24
3rd Support Level 3.14

See More

52-Week High 5.74
Fibonacci 61.8% 3.97
Last Price 3.62
Fibonacci 50% 3.43
Fibonacci 38.2% 2.88
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.